Study on the Long-Term Safety of Pirtobrutinib (LY3527727)
Sponsor: Eli Lilly and Company
ClinicalTrials ID:NCT06876649
This study is designed to monitor the long-term safety and effectiveness of the drug pirtobrutinib for participants who have completed earlier clinical trials involving this medication. Participants from these previous studies can continue their treatment or follow-up visits under this new study framework.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the long-term safety and effectiveness of pirtobrutinib, a medication that has been tested in earlier clinical trials. Participants who were part of these previous studies can join this new study to continue receiving the medication or to have follow-up visits. This study combines information from different trials to provide a comprehensive understanding of pirtobrutinib's long-term effects.
Eligibility Criteria
Inclusion Criteria
- Currently participating in a Lilly-sponsored clinical study that involves pirtobrutinib.
Exclusion Criteria
- Pregnant or planning to become pregnant during the study or within 30 days after the last dose of the study treatment.
- Breastfeeding during the study or within 1 week after the last dose of the study treatment.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California Medical Center | 94143-2204 | San Francisco | California |
| Sylvester Comprehensive Cancer Center | 33136-1002 | Miami | Florida |
| Florida Cancer Specialists | 34232-6422 | Sarasota | Florida |
| The Emory Clinic | 30322-1013 | Atlanta | Georgia |
| Northwestern University | 60611-3013 | Chicago | Illinois |
| Dana-Farber Cancer Institute | 02215 | Boston | Massachusetts |
| Mayo Clinic- Minnesota | 55905 | Rochester | Minnesota |
| University Of Nebraska Medical Center | 69198 | Omaha | Nebraska |
| Northwell Health | 11042-1118 | Lake Success | New York |
| Memorial Sloan-Kettering Cancer Center (MSKCC) - New York | 10065-6007 | New York | New York |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.